VRTX · News · 20261103N

Operating Expense Trends

VERTEX PHARMACEUTICALS INC / MA · 2026-11-03 · Importance 20 · Surprise 24

Vertex’s third-quarter 2026 adjusted earnings declined 0.8% year over year despite 12% revenue growth, with increased operating expenses cited as an offset. A separate earnings report attributed the EPS miss partly to increased spending for development of new franchises. The coverage also cited R&D investments and Crinetics acquisition costs, but did not quantify those expenses.

Key facts

• Vertex's stock fell 3.61% on November 3 following its Q3 results; the item attributed the adjusted EPS miss to a surge in operating expenses, R&D investment, and Crinetics acquisition costs. source